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1396Trends in the Use and Outcomes of Ventricular Assist Devices Among
Medicare Beneficiaries, 2006 Through 2011Objectives This study sought to examine trends in mortality, readmission, and costs among Medicare beneﬁciaries
receiving ventricular assist devices (VADs) and associations between hospital-level procedure volume and
outcomes.Background VADs are an option for patients with advanced heart failure, but temporal changes in outcomes and associations
between facility-level volume and outcomes are poorly understood.Methods This is a population-based, retrospective cohort study of all fee-for-service Medicare beneﬁciaries with heart failure
who received an implantable VAD between 2006 and 2011. We used Cox proportional hazards models to examine
temporal changes in mortality, readmission, and hospital-level procedure volume.Results Among 2,507 patients who received a VAD at 103 centers during the study period, the in-hospital mortality
decreased from 30% to 10% (p < 0.001), the 1-year mortality decreased from 42% to 26% (p < 0.001), and the
all-cause readmission was frequent (82% and 81%; p ¼ 0.70). After covariate adjustment, in-hospital and 1-year
mortality decreased (p < 0.001 for both), but the all-cause readmission did not change (p ¼ 0.82). Hospitals with
a low procedure volume had higher risks of in-hospital mortality (risk ratio: 1.72; 95% conﬁdence interval [CI]: 1.28
to 2.33) and 1-year mortality (risk ratio: 1.55; 95% CI: 1.24 to 1.93) than high-volume hospitals. Procedure volume
was not associated with risk of readmission. The greatest cost was from the index hospitalization and remained
unchanged ($204,020 in 2006 and $201,026 in 2011; p ¼ 0.21).Conclusions Short- and long-term mortality after VAD implantation among Medicare beneﬁciaries improved, but readmission
remained similar over time. A higher volume of VAD implants was associated with lower risk of mortality but not
readmission. Costs to Medicare have not changed in recent years. (J Am Coll Cardiol 2014;63:1395–404) ª 2014
by the American College of Cardiology FoundationUntil the emergence of ventricular assist devices
(VADs), treatment options for the 250,000 patients in
the United States with end-stage heart failure were
limited to heart transplantation. Yet, organ availability
has allowed only w2,000 transplantations each year
(1–3). Patients with advanced heart failure often have
comorbid conditions that preclude consideration of heart
transplantation. The transition of implantable VADs
from large, mechanically complex pulsatile devices best
suited for short-term use to smaller continuous-ﬂow
pumps has increased acceptance of the technology as a
therapeutic option (4).
Early experiences with VADs in community practice were
accompanied by high morbidity, mortality, and costs (5).
Efforts to improve outcomes have focused on enhancements in
VAD technology (6,7), reﬁnements in patient selection (8–11),
organization of care around multidisciplinary teams (12), and
patient-centered instruction (13). In addition, Joint Com-
mission standards require surgeons to perform a minimum
of 10 VAD placements within 3 years to achieve certiﬁcation
to use VADs as permanent therapy (14).
The Centers for Medicare & Medicaid Services (CMS)
recently examined policies for reimbursement for VADs for
Medicare beneﬁciaries. We sought to describe trends in short-
and long-term mortality, readmission, volume-outcome
relationships, costs among all fee-for-service Medicare beneﬁ-
ciaries receiving VADs between 2006 and 2011.Methods
Data sources and study population. We used a 100%
sample of Medicare inpatient claims and associated de-
nominator ﬁles for this study. The inpatient ﬁles contain
institutional claims for services covered under Medicare Part
A. We used information about procedures, diagnoses, ser-
vice dates, admission urgency, and discharge status from
these ﬁles. The denominator ﬁles contain demographic in-
formation, death dates (if applicable), and Medicare eligi-
bility and enrollment history. We used data from 2005
through 2011, although data from the ﬁrst year were used
solely for identiﬁcation of comorbid conditions and previous
procedures for selected beneﬁciaries.
We identiﬁed all beneﬁciaries enrolled in fee-for-service
Medicare who had a claim for an implantable VAD (In-
ternational Classiﬁcation of Diseases, Ninth Revision,
Clinical Modiﬁcation [ICD-9-CM] procedure code 37.66)
between January 1, 2006 and December 31, 2011. We
required a diagnosis of heart failure (ICD-9-CM diagnosis
code 428.x, 402.x1, 404.x1, or 404.x3) or cardiogenic shock
(785.51) in any position on the claim for the hospital
admission. We excluded beneﬁciaries who had a claim
for any of the following procedures during the admission
or in the 30 days before the VAD implantation: coronary
artery bypass graft surgery (ICD-9-CM procedure code
36.1x), heart transplantation (37.51 or 37.52), open-heart
Abbreviations
and Acronyms
CI = conﬁdence interval
CMS = Centers for Medicare
& Medicaid Services
ICD-9-CM = International
Classiﬁcation of Diseases-
Ninth Revision-Clinical
Modiﬁcation
STS = Society of
Thoracic Surgeons
VAD = ventricular assist
device
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1397valvuloplasty without replacement (35.11–35.14), open-
heart valve replacement (35.21–35.28), cardiotomy (37.11),
or receipt of a nonimplantable VAD (37.62 or 37.65).
Outcomes. All outcomes were based on Medicare inpatient
claims and mortality data. In-hospital outcomes of interest
were total length of stay and post-procedure length of stay.
We summarized mortality in 2 ways: in-hospital mortality
and mortality within 1 year after VAD implantation.
Among patients discharged alive, we also examined rates of
heart transplantation, all-cause readmission, and cardiovas-
cular readmission (diagnosis-related groups 104–112,
115–118, 121–145, 479, 514–518, 525–527, 535, 536, and
547–558 before October 1, 2007 or 215–238, 242–254,
258–262, and 280–316 on or after October 1, 2007) in the
year after discharge. Data for patients who did not experi-
ence an event during the mortality or readmission follow-up
period were censored at either the end of claims data
availability on December 31, 2011, or the date of enrollment
in a Medicare-managed care plan.
We also calculated payments made by Medicare to hos-
pitals for inpatient care of these patients during the index
hospitalization and, for those eligible, in the year after
discharge. Patients eligible for the post-discharge cost
analysis included those discharged alive who did not have
data censored due to the end of claims data availability or to
enrollment in Medicare-managed care. Patients who died or
underwent heart transplantation were included, but reported
costs reﬂect only the time that patients spent with the VAD
implanted and do not include costs for or after a hospital
admission for transplantation. We adjusted costs for inﬂa-
tion to 2010 U.S. dollars using the medical care component
of the Consumer Price Index.
Finally, for the same patients eligible for the post-
discharge cost analysis described, we counted the number
of hospitalizations for acute care in the year after discharge.
Comorbid conditions. We identiﬁed diabetes mellitus,
coronary heart disease, peripheral vascular disease, cere-
brovascular disease, hypertension, chronic obstructive pul-
monary disease, renal disease, liver disease, cancer, and
valvular heart disease using previously validated coding
algorithms (15,16). We also identiﬁed atrial ﬁbrillation
or ﬂutter (ICD-9-CM diagnosis codes 427.31 or 427.32)
and ventricular tachycardia (427.1). For all comorbid con-
ditions, we searched diagnosis codes on claims from the
VAD implantation admission and any inpatient stays in the
previous year.
Statistical analysis. We present baseline patient charac-
teristics by year of VAD implantation, showing categorical
variables as frequency with percentage and continuous var-
iables as mean with SD. To test for differences between
years, we used the chi-square test for categorical variables
and the Kruskal-Wallis test for continuous variables. We
also present the number of VAD implantations per hospital
in each year.
We present in-hospital mortality by year using frequencies
with percentages. We present total length of stay andpost-procedure length of stay by
implantation year using bothmean
and SD and median and inter-
quartile range. We tested for
trends across years for each of these
outcomes using the Cochran-
Mantel-Haenszel nonzero corre-
lation statistic. Tests involving
length of stay were rank based.
We calculated the incidence of
1-year mortality, heart trans-
plantation, all-cause readmission,
and cardiovascular readmission
by year using the cumulative
incidence function to account for both data censoring and
competing risks. We treated death and heart transplantation
as competing risks for each other and for both readmission
outcomes. This approach had the effect of describing event
rates over the duration of each patient’s VAD experience.
We tested for differences between years using the Gray test.
We present costs for the index hospitalization and for
inpatient care in the year after discharge, by implantation
year, using both mean and SD and median and interquartile
range. We tested for trends over time using rank-based
Cochran-Mantel-Haenszel nonzero correlation statistics.
To place post-discharge costs and number of hospitaliza-
tions from the VAD cohort in context, we compared them
with post-discharge costs and number of hospitalizations
from 2 other hospitalized cohorts: patients with heart failure
(primary ICD-9-CM diagnosis code 428.x, 402.x1, 404.x1,
or 404.x3) and patients undergoing heart transplantation
(ICD-9-CM procedure code 37.51). We limited the heart
failure cohort to patients 65 years of age and older and
matched them by age, sex, and year of hospitalization in a
4:1 ratio to patients in the VAD cohort. We did not limit
the heart transplantation cohort by age because of the
limited number of patients and the nearly identical age
distribution compared with the VAD cohort. We tested for
differences in post-discharge costs and number of hospital-
izations between each of these cohorts and the VAD cohort
using the Wilcoxon test.
In a post-hoc analysis, we identiﬁed common reasons for
readmission using the principal diagnoses of all inpatient
readmission claims. We used regression models to estimate
the relative risks associated with patient characteristics, co-
morbid conditions, hospital admission information, and year
on in-hospital mortality, 1-year mortality, and 1-year all-
cause readmission. We modeled in-hospital mortality using
generalized linear model methods, specifying Poisson errors
and a log link function, which allowed us to estimate relative
risks directly (17). Use of random intercepts allowed us to
account for clustering at the hospital level. We modeled both
1-year outcomes using competing risks regression methods
(18). Results from this method are similar to results from
Cox regression models, except that, like the cumulative
incidence function, they also account for competing risks.
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1398We also explored associations between annual hospital
procedure volume and each outcome. We categorized each
hospital in each year as having low volume (1 to 3 implan-
tations), medium volume (4 to 8 implantations), or high
volume (9 implantations). We summarized patient-level
outcomes in each group of hospitals as in the primary
analysis. We tested for the association between volume and
in-hospital mortality, controlling for year, using a stratiﬁed
Cochran-Mantel-Haenszel nonzero correlation statistic. We
tested for associations between procedure volume and the
other outcomes, controlling for year, using a stratiﬁed Gray
test. We estimated adjusted associations between procedure
volume and patient-level outcomes by adding the procedure
volume category to the regression models.
We used SAS version 9.3 (SAS Institute Inc., Cary, North
Carolina) for all analyses. The Institutional Review Board
of the Duke University Health System approved the study.Results
We identiﬁed 2,507 patients who received an implantable
VAD at 103 centers between 2006 and 2011. Of those, 896
were elective procedures and 1,611 were nonelective pro-
cedures. Procedure volume increased from 192 in 2006 to
622 in 2011. Demographic characteristics and theTable 1 Characteristics of the Study Population by Year of Ventricul
2006
(N ¼ 192)
2007
(N ¼ 241) (
Age, yrs 57.9  12.9 60.3  12.1 58
Male 159 (82.8) 202 (83.8) 2
Race
Black 41 (21.4) 51 (21.2)
White 139 (72.4) 178 (73.9) 2
Other/unknown 12 (6.3) 12 (5.0)
Comorbid conditions
Atrial ﬁbrillation/ﬂutter 108 (56.3) 134 (55.6) 1
Cancer * 11 (4.6)
Cerebrovascular disease 17 (8.9) 23 (9.5)
Chronic obstructive pulmonary disease 96 (50.0) 126 (52.3) 1
Coronary heart disease 124 (64.6) 173 (71.8) 2
Diabetes mellitus 67 (34.9) 92 (38.2) 1
Hypertension 127 (66.1) 152 (63.1) 1
Liver disease 13 (6.8) 42 (17.4)
Peripheral vascular disease 15 (7.8) 21 (8.7)
Renal disease 98 (51.0) 133 (55.2) 1
Valvular heart disease 106 (55.2) 131 (54.4) 1
Ventricular tachycardia 87 (45.3) 146 (60.6) 1
Implantation information
Shock diagnosis 52 (27.1) 88 (36.5) 1
Elective admission 48 (25.0) 77 (32.0)
Volume at implantation hospitaly
Low (1–3) 80 (41.7) 80 (33.2)
Medium (4–8) 71 (37.0) 89 (36.9) 1
High (9) 41 (21.4) 72 (29.9) 1
Values are mean  SD or n (%). *Data not shown when 10 patients. yNumber of ventricular assist deprevalence of most comorbid conditions were consistent over
time (Table 1). We observed increases in shock diagnosis
(27% to 44%; p < 0.001) and elective admissions for VAD
placement (25% to 41%; p < 0.001).
Table 2 shows the observed event rates. There were sig-
niﬁcant reductions over time in both in-hospital mortality
(30% to 10%; p < 0.001) and 1-year mortality (42% to 26%;
p < 0.001). The Online Figure shows the cumulative inci-
dence curves for all-cause mortality by year. Total and post-
procedure length of stay decreased over time from 46 days
to 33 days (p < 0.001) and from 33 days to 24 days
(p < 0.001), respectively. The incidence of heart trans-
plantation within 1 year decreased from 32% to 14%
(p < 0.001). Observed 1-year all-cause and cardiovascular
readmission remained steady. Online Table 1 shows the
results of the post-hoc analysis examining the contributing
causes for readmission.
After multivariable adjustment, year of VAD implanta-
tion was a signiﬁcant predictor of in-hospital and 1-year
mortality but not all-cause readmission (Table 3). Compared
with 2008, patients receiving a VAD in 2006 had a relative
risk of 2.03 for in-hospital mortality and 2.18 for 1-year
mortality. In contrast, patients receiving a VAD in 2011 had
a relative risk of 0.60 for in-hospital mortality and 0.77 for
1-year mortality.ar Assist Device Implantation
Year of Implantation
p Value
2008
N ¼ 310)
2009
(N ¼ 460)
2010
(N ¼ 682)
2011
(N ¼ 622)
.0  12.1 58.3  12.4 60.7  11.6 61.8  12.4 <0.001
46 (79.4) 379 (82.4) 552 (80.9) 499 (80.2) 0.71
0.82
68 (21.9) 106 (23.0) 158 (23.2) 135 (21.7)
20 (71.0) 327 (71.1) 490 (71.8) 462 (74.3)
22 (7.1) 27 (5.9) 34 (5.0) 25 (4.0)
56 (50.3) 225 (48.9) 368 (54.0) 435 (69.9) <0.001
* 18 (3.9) 24 (3.5) 23 (3.7) 0.61
34 (11.0) 53 (11.5) 66 (9.7) 73 (11.7) 0.73
74 (56.1) 267 (58.0) 370 (54.3) 449 (72.2) <0.001
14 (69.0) 320 (69.6) 471 (69.1) 478 (76.8) 0.005
32 (42.6) 193 (42.0) 302 (44.3) 316 (50.8) <0.001
99 (64.2) 299 (65.0) 486 (71.3) 515 (82.8) <0.001
41 (13.2) 70 (15.2) 135 (19.8) 134 (21.5) <0.001
29 (9.4) 49 (10.7) 67 (9.8) 113 (18.2) <0.001
46 (47.1) 210 (45.7) 346 (50.7) 416 (66.9) <0.001
31 (42.3) 182 (39.6) 268 (39.3) 366 (58.8) <0.001
92 (61.9) 266 (57.8) 399 (58.5) 386 (62.1) 0.002
05 (33.9) 174 (37.8) 263 (38.6) 275 (44.2) <0.001
79 (25.5) 171 (37.2) 267 (39.1) 254 (40.8) <0.001
<0.001
70 (22.6) 91 (19.8) 75 (11.0) 69 (11.1)
38 (44.5) 164 (35.7) 182 (26.7) 249 (40.0)
02 (32.9) 205 (44.6) 425 (62.3) 304 (48.9)
vice implantations in the year during which the patient underwent an implantation.
Table 2 Observed Event Rates by Year of Ventricular Assist Device Implantation
Year of Implantation
p Value
2006
(N ¼ 192)
2007
(N ¼ 241)
2008
(N ¼ 310)
2009
(N ¼ 460)
2010
(N ¼ 682)
2011
(N ¼ 622)
Mortality
In hospital 57 (29.7) 50 (20.8) 49 (15.8) 52 (11.3) 85 (12.5) 63 (10.1) <0.001
Within 1 yr 79 (41.8) 87 (36.3) 83 (27.0) 104 (22.9) 176 (26.1) 117 (25.7) <0.001
Total length of stay, days <0.001
Mean  SD 45.9  41.5 46.8  38.8 46.1  31.4 40.1  27.9 35.5  25.3 32.9  20.3
Median (IQR) 35 (22–51) 39 (24–58) 39 (25–59) 33 (22–48) 30 (20–43) 28 (20–40)
Post-procedure length of stay, d <0.001
Mean  SD 32.9  35.2 35.8  37.1 33.0  26.7 29.2  23.9 25.6  22.1 23.8  17.4
Median (IQR) 23 (14–37.5) 27 (17–43) 25 (15–42) 22 (15–33) 20 (14–30) 18.5 (14–28)
Index hospitalization
costs to Medicare, $*
0.21
Mean  SD 204,020  141,358 203,028  95,283 220,071  115,179 220,044  132,029 211,056  93,248 201,026  81,461
Median (IQR) 179,605 (145,008–229,220) 186,257 (155,140–244,762) 200,665 (166,815–262,248) 204,750 (171,054–243,249) 205,395 (170,631–248,635) 196,715 (168,462–236,145)
Eligible for post-discharge eventsy 131 189 257 406 596 555
Post-discharge events
within 1 yr
All-cause readmission 105 (81.8) 157 (84.3) 222 (87.5) 336 (83.8) 479 (81.9) 344 (81.1) 0.70
Cardiovascular
readmission
61 (51.0) 76 (42.1) 121 (49.5) 198 (50.7) 270 (47.4) 169 (42.6) 0.42
Heart transplantation 40 (31.7) 54 (29.0) 87 (34.4) 100 (25.2) 114 (19.6) 42 (13.8) <0.001
Eligible for post-discharge costsz 127 188 253 393 538 d
Inpatient costs within
1 yr, $*
0.01
Mean  SD 41,532  65,259 37,056  55,980 38,062  64,629 36,025  49,765 40,217  57,242 d
Median (IQR) 13,081 (0–46,416) 16,512 (0–45,691) 15,440 (0–44,683) 16,886 (2,078–48,462) 19,067 (4,972–52,142) d
Values are n (%) unless otherwise indicated. *Costs are expressed in 2010 U.S. dollars. yNumber of patients eligible for heart transplantation and readmission events. zNumber of patients discharged alive and not enrolled in Medicare-managed care during the subsequent year.
Only costs “on VAD” are reﬂected. No costs are accrued after an admission for heart transplantation.
IQR ¼ interquartile range.
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Table 3 Results of Multivariable Models for Each Outcome
In-Hospital Mortality Mortality at 1 Year All-Cause Readmission at 1 Year
RR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Age (per 5 yrs) 1.09 (1.04–1.14) <0.001 1.11 (1.06–1.16) <0.001 0.98 (0.95–1.00) 0.04
Male 1.17 (0.90–1.53) 0.24 1.13 (0.88–1.43) 0.34 0.90 (0.79–1.03) 0.12
Race 0.86* 0.32* 0.90*
Black 1.06 (0.82–1.38) 0.64 1.15 (0.91–1.45) 0.24 1.02 (0.89–1.16) 0.81
White 1.00 (reference) d 1.00 (reference) d 1.00 (reference) d
Other/unknown 0.97 (0.65–1.44) 0.88 1.22 (0.86–1.74) 0.26 1.05 (0.84–1.32) 0.67
Comorbid condition
Atrial ﬁbrillation or ﬂutter 0.95 (0.78–1.15) 0.58 0.97 (0.81–1.16) 0.74 1.09 (0.98–1.21) 0.12
Cancer 1.34 (0.86–2.09) 0.19 1.26 (0.82–1.93) 0.29 0.88 (0.68–1.15) 0.36
Cerebrovascular disease 1.65 (1.28–2.12) <0.001 1.64 (1.31–2.06) <0.001 1.04 (0.88–1.23) 0.64
Chronic obstructive pulmonary disease 0.77 (0.64–0.94) 0.009 0.85 (0.72–1.02) 0.08 0.97 (0.87–1.08) 0.62
Coronary heart disease 1.10 (0.87–1.39) 0.43 1.17 (0.94–1.46) 0.16 1.05 (0.93–1.18) 0.46
Diabetes mellitus 1.13 (0.93–1.37) 0.21 1.17 (0.98–1.39) 0.09 1.13 (1.02–1.26) 0.02
Hypertension 0.85 (0.68–1.07) 0.16 0.94 (0.76–1.16) 0.57 1.03 (0.91–1.16) 0.68
Liver disease 2.21 (1.79– 2.72) <0.001 2.06 (1.70–2.49) <0.001 0.85 (0.74–0.98) 0.03
Peripheral vascular disease 1.10 (0.82–1.47) 0.52 1.07 (0.82–1.40) 0.60 1.05 (0.89–1.23) 0.56
Renal disease 1.37 (1.12–1.68) 0.003 1.29 (1.07–1.55) 0.008 1.00 (0.90–1.12) 0.93
Valvular heart disease 0.73 (0.60–0.89) 0.002 0.71 (0.59–0.85) <0.001 1.00 (0.90–1.10) 0.93
Ventricular tachycardia 0.79 (0.65–0.95) 0.01 0.79 (0.66–0.93) 0.005 0.97 (0.87–1.07) 0.51
Elective procedure 0.80 (0.65–0.99) 0.04 0.82 (0.68–0.99) 0.04 1.00 (0.90–1.12) 0.94
Index diagnosis of shock 0.87 (0.71–1.06) 0.17 0.98 (0.82–1.17) 0.82 0.83 (0.74–0.92) <0.001
Implantation year <0.001* <0.001* 0.82*
2006 2.03 (1.44–2.87) <0.001 2.18 (1.55–3.06) <0.001 0.97 (0.75–1.25) 0.82
2007 1.22 (0.86–1.74) 0.26 1.53 (1.10–2.13) 0.01 0.90 (0.73–1.12) 0.35
2008 1.00 (reference) d 1.00 (reference) d 1.00 (reference) d
2009 0.70 (0.49–0.98) 0.04 0.73 (0.52–1.02) 0.06 1.00 (0.83–1.19) 0.96
2010 0.70 (0.51–0.96) 0.03 0.88 (0.65–1.18) 0.38 0.91 (0.77–1.08) 0.29
2011 0.60 (0.42–0.84) 0.003 0.77 (0.56–1.05) 0.10 0.94 (0.79–1.12) 0.51
*Group p value.
CI ¼ conﬁdence interval; HR ¼ hazard ratio; RR ¼ risk ratio.
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1400Over the study period, the proportion of VAD implan-
tations at high-volume centers increased from 21% to 49%
(Table 1). Mean procedure volume per hospital increased
from 3 to 6 (Online Table 2). The number of hospitals
increased from 64 to 103. The mean number of cumulative
VAD implantations per hospital increased from 3.0 to 23.6.
In 2006, 73% of hospitals were low-volume centers, 20%
were medium-volume centers, and 6% were high-volume
centers. In 2011, 34% of hospitals were low-volume cen-
ters, 43% were medium-volume centers, and 23% were
high-volume centers.
Low-volume hospitals had higher inpatient and 1-year
mortality than high-volume hospitals (Table 4). In con-
trast, observed event rates for all-cause and cardiovascular
readmission were similar over time, and this observation
was consistent within each volume group. Overall adjusted
risk ratios associated with hospital procedure volume con-
trolling for year showed that low-volume hospitals (1.72; 95%
conﬁdence interval [CI]: 1.28 to 2.33; p < 0.001) and
medium-volume hospitals (1.33; 95% CI: 1.04 to 1.72;
p ¼ 0.03) had higher risks of in-hospital mortality than high-
volume hospitals (Fig. 1). For 1-year mortality, low-volume
hospitals had higher risk than high-volume hospitals (hazardratio [HR]; 1.55; 95% CI: 1.24 to 1.93; p< 0.001); there was
no signiﬁcant difference between medium- and high-volume
hospitals (HR: 1.12; 95% CI: 0.92 to 1.37; p ¼ 0.25).
There were no signiﬁcant differences in all-cause readmission
and cardiovascular readmission on the basis of hospital
volume.
Mean Medicare payments for the index hospitalization
were $210,021 (SD: $106,241), and mean Medicare pay-
ments for inpatient care at 1 year were $38,469 (SD:
$57,258). Both amounts remained relatively unchanged over
time. Among patients discharged alive after heart trans-
plantation, mean Medicare payments for inpatient care at
1 year were $26,301 (SD: $51,966) (p < 0.001). The mean
number of hospitalizations in the year after discharge were
2.0 for VADs (SD: 2.1) versus 1.6 for heart transplantations
(SD: 1.9) (p < 0.001). Among patients 65 years of age and
older, mean 1-year inpatient payments after discharge from a
VAD hospitalization were $39,528 (SD: $55,999), and
mean 1-year inpatient payments after discharge from a heart
failure hospitalization were $23,813 (SD: $35,759) (p <
0.001). The mean number of hospitalizations in the year
after discharge were 1.8 for VADs (SD: 2.1) and 1.9 for
heart failure (SD: 1.9) (p ¼ 0.15).
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Temporal trends in outcomes associated with device tech-
nology, such as VADs, provide insights into the evolution
and diffusion of the technology for clinical care. Our study
had 5 important ﬁndings regarding VAD use and outcomes
among fee-for-service Medicare beneﬁciaries. First, in-
hospital and 1-year mortality rates after VAD implantation
have improved. Second, although procedural volumes are
improving, a large number of centers continue to implant
limited numbers of VADs. Third, low VAD volume re-
mains associated with higher in-hospital and 1-year mor-
tality, but not with readmission. Fourth, the total length of
stay associated with VAD implantations commonly exceeds
1 month, and readmissions are frequent. Finally, Medicare
spending was unchanged over time, and the greatest cost was
associated with the index hospitalization.
When ﬁrst-generation pulsatile VADs were introduced,
advanced heart failure and severity of illness coupled with
technical challenges of surgical implantation made mortality
reduction the primary focus for treating physicians. How-
ever, intermediate-term survival remained poor because of
device-related complications (19). After the transition to
more durable continuous-ﬂow devices in 2008, survival
improved to 55% at 2 years and continues to improve
(4,20,21). We saw a similar trend in increased survival over
time in our analysis, particularly after 2008. Also, implan-
tation year was a signiﬁcant predictor of in-hospital and
1-year mortality, with relative risk of mortality decreasing
signiﬁcantly after 2008. Although this decrease in mortalityTable 4 Observed Event Rates by Year and Hosp
2006 2007
In-hospital mortality, %
Low procedure volume (1–3) 38.8 28.8
Medium procedure volume (4–8) 26.8 20.2
High procedure volume (9) 17.1 12.5
1-yr mortality, %
Low procedure volume (1–3) 50.3 45.2
Medium procedure volume (4–8) 37.5 33.8
High procedure volume (9) 32.8 29.4
Heart transplantation at 1 yr, %
Low procedure volume (1–3) 39.1 32.6
Medium procedure volume (4–8) 37.1 28.6
High procedure volume (9) 13.1 26.2
All-cause readmission at 1 yr, %
Low procedure volume (1–3) 84.8 83.6
Medium procedure volume (4–8) 83.5 82.7
High procedure volume (9) 74.7 86.8
Cardiovascular readmission at 1 yr, %
Low procedure volume (1–3) 56.8 36.0
Medium procedure volume (4–8) 49.4 37.5
High procedure volume (9) 46.4 52.5
*Testing differences by hospital-level implantation volume, controlling for yemay be due to improvements in technology, there has also
been a better understanding of appropriate patient selection
with an emphasis on implantation in earlier stages of
cardiogenic shock and more experience with implanting
VADs and managing patients post-operatively.
In contrast, total length of stay for VAD implantation
continues to exceed 30 days for most centers, and 1-year
readmission rates remain high, driven largely by post-
operative complications such as infection (22–24), bleeding
(25–27), thrombosis (28), heart failure, and arrhythmias
(29,30). Although stroke or transient ischemic attack is an
important complication of VADs, it was not a frequent
cause of readmission at 1 year in our study or in a recent
analysis of readmissions (31). In contrast, infection is com-
mon in the driveline or pump pocket, and bleeding has
become more prominent due to the unique physiology
created by nonpulsatile blood ﬂow.
We are now in a state of transition in the longitudinal care
path of patients receiving VAD therapy. Although early
survival has improved markedly, the transition from the
operating room to the post-discharge environment demands
attention. Most centers have established multidisciplinary
teams of physicians, VAD coordinators, nurses, physical
therapists, and others who specialize in identifying post-
operative complications and managing patients to improve
other outcomes such as readmission. However, VAD care is
further complicated by multiple other problems, including
caregiver burden and limited hospital infrastructure to
manage patients with minimally pulsatile circulation.
Further, there is a continually evolving knowledge base onital Implant Volume
Year
p Value*2008 2009 2010 2011
<0.001
14.3 16.5 18.7 10.1
15.9 13.4 12.1 10.0
16.7 7.3 11.5 10.2
0.03
28.8 22.3 29.6 21.3
20.3 30.1 25.6 24.3
35.1 17.3 25.7 27.2
<0.001
40.4 36.0 25.6 19.4
38.5 28.6 23.6 13.6
24.4 18.4 17.0 12.5
0.39
91.2 90.4 84.4 72.2
84.9 84.4 82.8 87.4
88.8 80.7 81.1 78.3
0.75
33.6 59.3 58.1 24.3
54.5 46.6 43.0 41.8
53.2 50.5 47.6 45.9
ar.
Figure 1 Adjusted Relative Risks of Each Outcome by Annual Volume of Ventricular Assist Device Implantation
Risk ratios are shown for in-hospital mortality. Hazard ratios are shown for all other outcomes. All models control for patient characteristics, comorbid conditions,
implantation admission information, and year of implantation (Table 3). p Values for differences between center volume categories by outcome are as follows: in-hospital
mortality, p ¼ 0.002; 1-year mortality, p < 0.001; 1-year all-cause readmission, p ¼ 0.48; 1-year cardiovascular readmission, p ¼ 0.80. CI ¼ conﬁdence interval.
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utility of existing therapeutics for common adverse events
encountered during VAD support (32). We postulate that
the required elements of this accruing provider knowledge
base, psychosocial support, and healthcare infrastructure are
likely to be concentrated at larger centers implanting a large
number of VADs.
Conversely, the development of the clinical experience,
optimal infrastructure, and care efﬁciency to provide the
highest quality of care for patients undergoing VAD therapy
may be limited in the large number of centers that implant a
small number of VADs. We found that low-volume centers
have higher risks of in-hospital and 1-year mortality
compared with high-volume centers, but the minimal
threshold for center volume is uncertain. Our ﬁndings
suggest that implanting 9 VADs is associated with the
lowest inpatient mortality, but this volume is substantially
higher than the current certiﬁcation requirements by the
Joint Commission and CMS for a minimum of 10 VADs
over a 3-year period. This number is also lower than the
minimal implantation volume of 15 that provided beneﬁt in
a risk model derived from clinical trial data with a second-
generation VAD (33). Our data also suggest that all-cause
and cardiovascular readmission rates did not differ by cen-
ter volume. Readmission is a complex issue due to comorbid
conditions, post-procedure complications, socioeconomic
status, and physician thresholds for readmission, amongother factors. Understanding the factors that drive read-
mission is critical to making VAD therapy a viable option
for patients with advanced heart failure.
Previous observational studies have shown a volume-
outcome relationship in which surgical procedures improve
with clinical experience (34,35). This phenomenon has also
been observed to a limited extent among clinical trial pa-
tients receiving pulsatile VADs who had improvements in
1-year mortality with increasing institutional experience
(36). Historically, examining VAD volume-outcome re-
lationships outside clinical trials has been challenging given
the limitations of registry information. Unlike the Inter-
agency Registry for Mechanically Assisted Circulatory
Support (INTERMACS) and the Society of Thoracic
Surgeons (STS) registry, which record VAD information,
Medicare data are not limited by patient consent (as is
INTERMACS) or variability in chart abstraction (as is the
STS registry). In addition, Medicare data include VADs
implanted under coverage with evidence development
(clinical trials) and capture costs, unlike the INTERMACS
and the STS registry.
To our knowledge, ours is the ﬁrst study to explore as-
sociations between center volume and outcomes in the
modern VAD era in all Medicare fee-for-service beneﬁ-
ciaries. Although an INTERMACS report for CMS
examined volume-outcome associations, the analysis
excluded younger, disabled beneﬁciaries (54% of patients in
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should be concentrated at centers of excellence that perform
a large number of procedures. This likely allows efﬁciency
and standardization from a multidisciplinary care heart
team. As centers grow in experience, so do standardized
approaches to common problems. However, overcoming
barriers to accessing advanced technology will require
expansion of centers with experience. As new VAD centers
develop, it will be important for them to link to leading
centers to easily disseminate best practices and leverage
experience. By having leading centers share best practices,
there is potential to build collective knowledge of best
practices in using new VAD technologies as they become
available.
In our analysis, we observed no signiﬁcant temporal
changes in Medicare spending for VADs. There are a
number of reasons for the lack of change. First, payment by
Medicare for the index procedure has not changed signiﬁ-
cantly over time (38). Second, downstream costs are driven
by readmission, which did not change during the study
period. Although heart failure is generally costly compared
with other Medicare diagnoses, our comparison among pa-
tients who were 65 years of age or older shows that there
may be room for improvement after discharge from a VAD
hospitalization. The mean 1-year inpatient costs after VAD
hospitalization were higher than those in a matched cohort
of patients discharged after a heart failure hospitalization.
Similarly, mean 1-year inpatient costs for VAD hospitali-
zation were higher than costs for patients discharged after
a heart transplantation. These estimates did not include
costs for skilled nursing, physician services, outpatient visits,
home health care, physical and occupational therapy, durable
medical equipment, and medications. Although the index
hospitalization for VADs represents the largest cost to
Medicare, subsequent inpatient costs may decrease over time
as readmission rates after implantation decrease.
Study limitations. First, results from fee-for-service
Medicare beneﬁciaries may not be generalizable to non-
Medicare patients. Speciﬁcally, the total number of im-
plantations at a particular center may not be accurately
reﬂected by this analysis depending on the payer mix.
However, national statistics show that Medicare paid for
48% of VAD implantations in 2011 (39), suggesting that
our results provide important information from the
perspective of the predominant payer. Second, this analysis
used administrative claims without any clinical data such as
type of device or initial intent of implantation. Although the
type of device changed over time, our analysis accounts for
temporal changes by year of implantation. Of note, most
centers switched over quickly to continuous ﬂow technology
(4). Although we were unable to determine the intent of the
device at the time of implantation, it may be appropriate to
remove this designation because a patient’s designation
changes over time on the basis of the clinical condition (40).
As for type of ventricular support, we were not able to
distinguish between left and right ventricular or biventricularsupport speciﬁcally using ICD-9-CM procedure codes.
Publicly reported data show that right ventricular and
biventricular support is rare (4). Finally, there were
measured and unmeasured confounders that may have
inﬂuenced the results.
Conclusions
In-hospital and 1-year mortality have improved over time,
whereas hospital length of stay and readmission have
remained relatively unchanged. Patients receiving VADs at
low-volume centers have a signiﬁcantly higher risk of in-
hospital and 1-year mortality compared with those
receiving VADs at high-volume centers, suggesting that
center volume and experience are important for optimal care
delivery in this area. In addition, examination of the rela-
tionship between center experience and outcomes may be
useful as accreditation agencies and payers reﬁne criteria for
implantation sites.Acknowledgment
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